Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Discovery & Development Drug Delivery, Vaccines

Cupping Combats COVID-19?

Credit : Katherine Hanlon / Unsplash.com

Though the origins of cupping are unclear – and, for some, controversial – a paper published by researchers at Rutgers University, New Jersey, USA, draws comparison between the ancient technique and a method for increasing uptake of DNA-based medicines, including vaccines for COVID-19 to patients.

In the traditional practice of cupping, one or several heated glass cups are placed on the skin, creating negative pressure and increasing blood flow. (Adherents of traditional Chinese medicine believe this facilitates the flow of “qi” – the term assigned to vital energy that is fundamental to the discipline but unproven by scientific inquiry.)

In the study at Rutgers, a smaller, handheld device operating on a similar mechanical principle was used on rats. Following a conventional vaccine injection, the 6 ml orifice was applied at the point of injection for 30 seconds, inflicting no pain and leaving no mark. It is thought that the force of suction against the skin then increases the uptake of vaccine particles by the dermis cells; certainly, when used on the Rutgers rats, the suction devices multiplied the subsequent immune response by roughly 100 times.

Study leader, Hao Lin, who has tried the method on himself, highlighted suction-based in vivo cutaneous DNA transfection as a highly-scalable platform for both laboratory and clinical applications for nucleic-acid-based therapeutics and vaccines. He also noted that minimal training was necessary for practitioners of the technique.

“We have demonstrated an alternative, safe, and effective transfection platform that yields high levels of transgene expression,” Lin said in a statement. “Because of the inherent advantages of DNA, not least of which is avoiding cold-chain requirements of other vaccines, this technology facilitates vaccination programs in remote regions of the world where resources are limited.”


Cell Therapeutics and Catalent Complete Technology Transfer

catalent logo

The technology transfer for BrainStorm's NurOwn® autologous cell therapy at Catalent’s facility has been finalized. NurOwn will be manufactured at Catalent’s world-class 32,000 square-foot cell therapy manufacturing facility in Houston.

Download


Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Angus Stewart

Angus is Associate Editor of The Medicine Maker

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register